Obesity (BMI ≥30) Annual Evaluation Checklist

Why Structured Annual Evaluation Matters for Obesity

Obesity is a chronic, relapsing disease with more than 200 documented complications. A single yearly encounter that addresses every domain, from anthropometrics to mental health, reduces five-year major adverse cardiovascular event (MACE) risk and gives clinicians a documented baseline for treatment response.

The 2022 American Diabetes Association Standards of Care state: "Obesity management is an integral component of the prevention and treatment of type 2 diabetes and should be addressed at every clinical encounter." [1] This reflects a broader shift in treating obesity as a primary diagnosis rather than a lifestyle choice.

The Scope of Obesity-Related Risk

Obesity increases the risk of at least 13 cancers, type 2 diabetes, heart failure, obstructive sleep apnea (OSA), nonalcoholic (now called metabolic-associated) steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), osteoarthritis, and depression. [2] Each of these conditions warrants targeted screening within the annual evaluation.

Who This Checklist Applies To

This checklist applies to adults aged 18 and older with a measured BMI of 30 kg/m² or above. Clinicians at HealthRX apply a modified version beginning at BMI 27 kg/m² when one or more weight-related comorbidities are present, consistent with FDA labeling for approved anti-obesity medications.

Section 1: Anthropometric and Vital Sign Assessment

Accurate measurement is the foundation of every annual evaluation. Body weight alone misses visceral adiposity, which predicts cardiometabolic risk independently of total body fat.

BMI Calculation and Interpretation

Measure height and weight in light clothing, no shoes. Calculate BMI as weight (kg) divided by height (m²). Document the BMI class: Class I (30.0 to 34.9), Class II (35.0 to 39.9), or Class III (>= 40.0). The World Health Organization notes that BMI classification at Asian-origin populations may need a lower cutoff of 27.5 for Class I obesity. [3]

Waist Circumference

Measure waist circumference at the iliac crest, at the end of a normal exhalation. High-risk thresholds are >102 cm in men and >88 cm in women. The Look AHEAD trial (N=5,145) showed that waist circumference reduction, not just BMI reduction, correlated with cardiovascular benefit. [4]

Blood Pressure

Target blood pressure in adults with obesity is <130/80 mmHg per 2017 ACC/AHA Hypertension Guidelines. [5] Measure with an appropriately sized large adult or thigh cuff, because an undersized cuff overestimates systolic pressure by up to 10 mmHg.

Resting Heart Rate and Oxygen Saturation

A resting heart rate above 100 bpm in a patient with obesity warrants thyroid testing and an OSA screen. Resting SpO2 below 94% suggests obesity hypoventilation syndrome and should prompt expedited polysomnography referral.

Section 2: Laboratory Evaluation

Labs reveal the metabolic consequences of excess adiposity and rule out secondary causes of weight gain. The following panel should be ordered at least annually, or more frequently when medications are being titrated.

Core Metabolic Panel

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides): Adiposity-driven atherogenic dyslipidemia often presents as elevated triglycerides and low HDL. The National Lipid Association 2019 Scientific Statement recommends fasting lipids every 1 to 5 years depending on cardiovascular risk. [6]
• HbA1c and fasting plasma glucose: The USPSTF recommends diabetes screening for adults aged 35 to 70 who are overweight or obese. [7] HbA1c >= 5.7% signals prediabetes; >= 6.5% confirms type 2 diabetes.
• Comprehensive metabolic panel (CMP): Assesses hepatic and renal function. AST and ALT elevations may indicate MASLD, present in up to 55% of adults with obesity. [8]
• TSH: Hypothyroidism causes weight gain of 5 to 10 kg in some patients and is easily missed without routine screening.
• CBC: Screens for iron-deficiency anemia, common after bariatric surgery and in women with PCOS.

Liver and Metabolic-Specific Add-Ons

Consider a FIB-4 score (calculated from age, AST, ALT, and platelet count) at every annual visit for patients with BMI >= 30 and any of: elevated ALT, type 2 diabetes, or metabolic syndrome. A FIB-4 <1.30 has a negative predictive value of 90% for advanced hepatic fibrosis. [9]

Hormonal and Specialty Labs

Order fasting insulin and HOMA-IR when prediabetes or PCOS is suspected. Add testosterone (total and free), LH, and FSH for women with irregular cycles and men with symptoms of hypogonadism. Testosterone deficiency in men with obesity is present in 40 to 50% of cases and independently predicts metabolic syndrome. [10]

Section 3: Comorbidity Screening

Cardiovascular Disease

Calculate the 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations at every annual visit. Patients with a score of 7.5% or above and LDL >= 70 mg/dL qualify for statin therapy discussion per ACC/AHA 2019 guidelines. [11]

A 12-lead ECG is not universally required but should be ordered for patients with a BMI >= 35 and any of: hypertension, type 2 diabetes, age >= 45 in men or >= 55 in women, or symptoms of chest pain and palpitations.

Obstructive Sleep Apnea

The STOP-BANG questionnaire is the validated two-minute screen for OSA in clinical practice. [12] Score >= 3 warrants home sleep apnea testing or polysomnography referral. OSA is present in approximately 40% of adults with obesity and frequently goes undiagnosed for years.

Metabolic-Associated Steatotic Liver Disease (MASLD)

Screen with hepatic ultrasound every 2 to 3 years for patients with persistently elevated transaminases or FIB-4 >= 1.30. The recent SUMO trial (N=971) demonstrated that semaglutide 2.4 mg reduced liver fat content by 31.4% versus 9.1% placebo at 72 weeks (P<0.001), adding a hepatic indication to GLP-1 receptor agonist therapy. [13]

Type 2 Diabetes and Prediabetes

Screen every year with HbA1c if prediabetes (5.7 to 6.4%) was found at a prior visit. The Diabetes Prevention Program (DPP, N=3,234) showed that intensive lifestyle intervention reduced diabetes incidence by 58% in high-risk adults, compared to 31% with metformin. [14] Document DPP referral in the chart for every patient with prediabetes.

Depression and Disordered Eating

Administer the PHQ-9 annually. A score of 10 or above indicates moderate-to-severe depression, which both increases weight gain risk and reduces treatment adherence. Screen separately for binge eating disorder with the QEWP-R or BES questionnaire, as binge eating disorder is present in 5 to 8% of adults seeking obesity treatment. [15]

Section 4: Medication and Supplement Review

Identify Weight-Promoting Medications

Many commonly prescribed drugs cause clinically significant weight gain. Review the full medication list at each annual visit. Common offenders include:

• Antipsychotics: olanzapine (average +4.2 kg at 10 weeks), clozapine, quetiapine
• Antidepressants: mirtazapine, paroxetine, amitriptyline
• Antiepileptics: valproate (average +6 kg per year), gabapentin, carbamazepine
• Insulin secretagogues: sulfonylureas (average +2 to 3 kg)
• Glucocorticoids: prednisone at >7.5 mg/day for >3 months causes visceral adiposity and adrenal suppression

Where therapeutically appropriate, switching to weight-neutral or weight-reducing alternatives (e.g., bupropion for depression, topiramate or zonisamide for epilepsy, SGLT-2 inhibitors for type 2 diabetes) reduces obesity pharmacotherapy burden.

Review Current Anti-Obesity Medications

Document dose, duration, efficacy (percentage body weight loss from baseline), tolerability, and adherence for any current anti-obesity medication. The FDA-approved options as of 2025 are:

| Medication | Mechanism | Expected Weight Loss | Notes | |---|---|---|---| | Semaglutide 2.4 mg/week SC (Wegovy) | GLP-1 RA | 14.9% at 68 weeks [16] | Approved 2021; CVOT data from SELECT trial | | Tirzepatide 15 mg/week SC (Zepbound) | GIP/GLP-1 RA | 20.9% at 72 weeks [17] | Approved 2023 | | Naltrexone-bupropion ER (Contrave) | Opioid antagonist/NDRI | 6.1% at 56 weeks [18] | Contraindicated with opioids | | Phentermine-topiramate ER (Qsymia) | Sympathomimetic/carbonic anhydrase inhibitor | 10.9% at 56 weeks [19] | Teratogenic; requires REMS | | Orlistat 120 mg TID (Xenical) | Pancreatic lipase inhibitor | 3.1% vs placebo at 1 year [20] | Fat-soluble vitamin malabsorption |

Section 5: Lifestyle and Behavioral Assessment

Dietary Pattern Review

Ask specifically about caloric intake pattern, meal timing, and ultra-processed food consumption rather than generic dietary quality. A 2019 NIDDK-funded crossover study (N=20) by Hall et al. Found that an ultra-processed diet caused 508 kcal/day excess intake versus an unprocessed diet over two weeks, independent of macronutrient ratios. [21]

Document whether the patient follows a specific dietary pattern (Mediterranean, low-carbohydrate, time-restricted eating) and quantify adherence. Modest caloric deficits of 500 to 750 kcal/day produce 0.5 to 1 kg/week weight loss without extreme restriction.

Physical Activity Assessment

Use the FITT framework: Frequency (days/week), Intensity (METs), Time (minutes/session), Type (aerobic vs. Resistance). The 2018 Physical Activity Guidelines for Americans recommend 150 to 300 minutes/week of moderate-intensity aerobic activity plus 2 sessions/week of muscle-strengthening. [22] Less than 60 minutes/week of moderate activity at baseline qualifies a patient for structured exercise referral.

Sleep and Stress

Chronic short sleep (<6 hours/night) elevates ghrelin and suppresses leptin, producing 385 kcal/day excess intake on average in a meta-analysis of 11 controlled studies. [23] Document sleep duration and quality alongside stress level using a validated scale (PSS-10 or the DASS-21).

Section 6: Treatment Escalation Decision Framework

The following stepwise framework is used by HealthRX clinicians to guide annual escalation decisions. It synthesizes the 2023 ACC/AHA/AACVPR obesity guideline, the Endocrine Society 2015 Clinical Practice Guideline on Pharmacological Management of Obesity, and FDA labeling for approved agents.

Step 1. Confirm BMI class and comorbidity burden. Patients at BMI >= 30 (any class) without comorbidities begin with intensive lifestyle intervention targeting >5% weight loss over 6 months.

Step 2. Add pharmacotherapy if lifestyle alone is insufficient. Indicate pharmacotherapy when <5% weight loss occurs after 3 to 6 months of lifestyle intervention, or immediately when BMI >= 35 with a serious comorbidity. Select agent based on comorbidity profile, contraindications, and patient preference.

Step 3. Escalate pharmacotherapy class if response is suboptimal. Switch from a lower-efficacy agent (e.g., orlistat, naltrexone-bupropion) to a GLP-1 receptor agonist or dual GIP/GLP-1 agonist if <5% weight loss is achieved at the maximum tolerated dose after 12 to 16 weeks.

Step 4. Evaluate bariatric surgery candidacy. Refer to a bariatric surgery program for formal evaluation when BMI >= 40 (Class III), or BMI >= 35 with type 2 diabetes, hypertension, OSA, or MASLD, per 2022 ASMBS/IFSO criteria. [24] Patients who have failed two or more pharmacotherapy trials at adequate doses are priority referrals.

Step 5. Maintain and monitor. After achieving >5% weight loss, continue the effective intervention indefinitely. Regain of >5% from nadir within 12 months indicates need for dose adjustment or regimen change.

Section 7: Preventive Care and Cancer Screening Integration

Adults with obesity require timely completion of standard preventive services, several of which are accelerated or adjusted by excess weight.

Cancer Screening

Colorectal cancer risk is 30% higher in adults with obesity compared to normal-weight adults. [25] The USPSTF recommends colonoscopy or stool DNA testing starting at age 45 for average-risk adults, and clinicians should document cancer screening status at each annual evaluation.

Endometrial cancer risk rises substantially with increasing BMI. Women with BMI >= 40 and abnormal uterine bleeding should be referred immediately for endometrial biopsy.

Bone Health

Patients on bariatric surgery programs or GLP-1 receptor agonists with inadequate calcium and vitamin D intake are at risk for secondary hyperparathyroidism. Order 25-OH vitamin D and PTH annually for any patient post-bariatric surgery and for those on long-term anti-obesity pharmacotherapy with restricted dietary intake.

Vaccination Status

Obesity (BMI >= 40) is classified as a high-risk condition for severe influenza by the CDC, and adults in this group should receive annual influenza vaccine, COVID-19 updated booster, and pneumococcal vaccination per age-appropriate ACIP schedules. [26]

Section 8: Documentation and Follow-Up Planning

Every annual evaluation should close with a written visit summary that includes:

1. Current weight, BMI, waist circumference, and percent change from baseline
2. Updated ASCVD 10-year risk score
3. Lab results with interpretation and any new diagnoses
4. Medication list with noted changes and rationale
5. Referrals placed (dietitian, sleep medicine, bariatric surgery, behavioral health)
6. Treatment goal for the next 12 months, expressed as percentage body weight loss

The Endocrine Society 2015 guideline states: "Clinicians should evaluate patients treated with anti-obesity medications for efficacy and safety at least monthly for the first 3 months, then at least every 3 months." [27] Between annual evaluations, follow-up intervals depend on treatment phase.

A 3-month follow-up after any medication initiation or dose change is the minimum standard at HealthRX. Patients achieving active weight loss (>= 1% per month) may extend to 6-month intervals after the first year if stable and adherent.